Department of Orthopaedics and Traumatology, University Medical Centre of the Johannes Gutenberg-University of Mainz, Mainz, Germany.
Int J Sports Med. 2019 Nov;40(12):803-809. doi: 10.1055/a-0915-2306. Epub 2019 Sep 2.
The use of injections to treat structural muscle injuries is controversially discussed. In our controlled in vitro study, we investigated the biological impact of Actovegin and Traumeel alone and in combination on primary human skeletal muscle cells. Cells were characterized by immunofluorescence staining for myogenic factor 5 (Myf5) and MyoD, and cultured with or without Actovegin and / or Traumeel. The effects of these agents were assayed by cell viability and gene expression of the specific markers MyoD, Myf5, neural adhesion molecule (NCAM), and CD31. Myotube formation was determined by myosin staining. Neither Actovegin nor Traumeel showed toxic effects or influenced cell viability significantly. High volumes of Actovegin down-regulated gene expression of NCAM after 3 days but had no effect on MyoD, Myf5, and CD31 gene expression. High volumes of Traumeel inhibited MyoD gene expression after 3 days, whereas after 7 days MyoD expression was significantly up-regulated. The combination of both agents did not significantly influence cell viability or gene expression. This is the first study demonstrating that Actovegin and Traumeel potentially modulate human skeletal muscle cells. The relevance of these in vitro findings has to be highlighted in further in vivo studies.
注射治疗在结构肌肉损伤中的应用存在争议。在我们的对照体外研究中，我们研究了 Actovegin 和 Traumeel 单独及联合对原代人骨骼肌细胞的生物学影响。通过免疫荧光染色鉴定肌生成因子 5 (Myf5) 和 MyoD 对细胞进行鉴定，并在有或没有 Actovegin 和/或 Traumeel 的情况下培养细胞。通过细胞活力和特定标记物 MyoD、Myf5、神经细胞黏附分子 (NCAM) 和 CD31 的基因表达来检测这些药物的作用。通过肌球蛋白染色确定肌管形成。Actovegin 和 Traumeel 均未显示出毒性作用或对细胞活力有显著影响。高体积的 Actovegin 在第 3 天下调了 NCAM 的基因表达，但对 MyoD、Myf5 和 CD31 的基因表达没有影响。高体积的 Traumeel 在第 3 天抑制了 MyoD 基因的表达，而在第 7 天 MyoD 表达则显著上调。两种药物的联合使用对细胞活力或基因表达没有显著影响。这是第一项证明 Actovegin 和 Traumeel 可能调节人骨骼肌细胞的研究。这些体外发现的相关性必须在进一步的体内研究中突出。
